<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01498692</url>
  </required_header>
  <id_info>
    <org_study_id>S2046A</org_study_id>
    <nct_id>NCT01498692</nct_id>
  </id_info>
  <brief_title>The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels</brief_title>
  <acronym>PLATINUM SV</acronym>
  <official_title>PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element™) for the Treatment of up to Two De Novo Coronary Artery Lesions - Small Vessel Sub-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™
      Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo
      atherosclerotic coronary artery lesions. The lesions can be located in vessels that are
      smaller than average-sized.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The wide-spread use of drug-eluting stents (DES) has evolved as standard of care in de novo
      lesions. The proposed study will evaluate the safety and effectiveness of PROMUS Element for
      the treatment of de novo atherosclerotic lesions in native coronary arteries. The study
      design is consistent with the draft guidance for industry titled, &quot;Coronary Drug-Eluting
      Stents - Nonclinical and Clinical Studies&quot; (March 2008).

      During the trial, thienopyridines must be administered according to the 2007 American College
      of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography
      and Interventions (SCAI) guidelines, which recommended that clopidogrel (75 mg daily) or
      ticlopidine (250 mg twice daily) be prescribed after stent implantation for at least 6 months
      in all patients, and for at least 12 months in patients who are not at high risk of bleeding.
      For sites in the United States, the use of prasugrel is not allowed as part of the PLATINUM
      Clinical Trial. For sites in other countries, prasugrel may be prescribed according to its
      approved dosing in countries in which it is available. For patients taking aspirin daily a
      loading dose is recommended; for patients who have not been taking aspirin daily, aspirin
      must be administered as a loading dose. Patients continue to take aspirin indefinitely to
      reduce the risk of thrombosis.

      This PLATINUM Small Vessel study is a sub-trial associated with the PLATINUM Workhorse
      Randomized Controlled Trial, which is registered under NCT00823212.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 Months</time_frame>
    <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel. The primary analysis set for the non-inferiority testing of the primary endpoint is the per-protocol analysis set. All randomized participants who received their assigned treatment are included in the per-protocol analysis set.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>6 Months</time_frame>
    <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>30 Days</time_frame>
    <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>12 Months</time_frame>
    <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>6 Months</time_frame>
    <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>30 Days</time_frame>
    <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) Related to the Target Vessel</measure>
    <time_frame>12 Months</time_frame>
    <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) Related to the Target Vessel</measure>
    <time_frame>6 months</time_frame>
    <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI) Related to the Target Vessel</measure>
    <time_frame>30 days</time_frame>
    <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death Related to the Target Vessel</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death Related to the Target Vessel</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death Related to the Target Vessel</measure>
    <time_frame>30 days</time_frame>
    <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization TLR)</measure>
    <time_frame>30 days</time_frame>
    <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>12 months</time_frame>
    <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>Any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC)Definition</measure>
    <time_frame>24 hours</time_frame>
    <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</measure>
    <time_frame>&gt;24 hr-30 days</time_frame>
    <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</measure>
    <time_frame>&gt;30 days-1 year</time_frame>
    <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Technical Success</measure>
    <time_frame>During the index procedure (minutes)</time_frame>
    <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Procedural Success</measure>
    <time_frame>Duration of Hospital Stay (average 1-2 days)</time_frame>
    <description>Defined as mean lesion diameter stenosis &lt;30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital MI, TVR, or cardiac death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PROMUS Element</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROMUS Element Coronary Stent System</intervention_name>
    <description>PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)</description>
    <arm_group_label>PROMUS Element</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be at least 18 years of age

          -  Patient (or legal guardian) understands study requirements and treatment procedures
             and provides written informed consent before any study-specific tests or procedures
             are performed

          -  For patients less than 20 years of age enrolled at a Japanese site, patient and
             patient's legal representative must provide written informed consent before any
             study-specific tests or procedures are performed

          -  Patient is eligible for percutaneous coronary intervention (PCI)

          -  Patient has documented stable angina pectoris or documented silent ischemia; or
             unstable angina pectoris

          -  Patient is an acceptable candidate for coronary artery bypass grafting (CABG)

          -  Patient has a left ventricular ejection fraction (LVEF) &gt;=30% as measured within 30
             days prior to enrollment

          -  Patient is willing to comply with all protocol-required follow-up evaluations

        Angiographic Inclusion Criteria (visual estimate):

        - Target lesion must be a de novo lesion located in a native coronary artery with a
        visually estimated reference vessel diameter ≥2.25 mm and &lt;2.5 mm. Target lesion length
        must measure ≤28 mm by visual estimate. Target lesion must be located in a major coronary
        artery or branch with visually estimated stenosis ≥50% and &lt;100% with Thrombolysis In
        Myocardial Infarction (TIMI) flow &gt;1.

        Exclusion Criteria:

          -  Patient has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
             acute myocardial infarction (MI)

          -  Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index
             procedure) and has elevated enzymes at time of index procedure as follows.

               -  Patients are excluded if any of the following criteria are met at time of the
                  index procedure.

                    -  If creatine kinase-myoglobin band (CK-MB) &gt;2× upper limit of normal (ULN),
                       the patient is excluded regardless of CK Total.

                    -  If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is &gt;2× ULN.

               -  If CK Total/CK MB are not used and Troponin is, patients are excluded if the
                  following criterion is met at time of index procedure.

                    -  Troponin &gt;1× ULN with at least one of the following.

               -  Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (eg,
                  &gt;1 mm ST segment elevation or depression in consecutive leads or new left bundle
                  branch block [LBBB]);

               -  Development of pathological Q waves in the ECG; or

               -  Imaging evidence of new loss of viable myocardium or new regional wall motion
                  abnormality.

        Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK
        MB (or Troponin if CK Total/CK MB are not used) must be documented prior to
        enrolling/randomizing the patient.

          -  Patient has received an organ transplant or is on a waiting list for an organ
             transplant

          -  Patient is receiving or scheduled to receive chemotherapy within 30 days before or
             after index procedure

          -  Patient is receiving oral or intravenous immunosuppressive therapy (ie, inhaled
             steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune
             disease (eg, human immunodeficiency virus, systemic lupus erythematosus, but not
             including diabetes mellitus)

          -  Patient is receiving chronic (&gt;=72 hours) anticoagulation therapy (eg, heparin,
             coumadin) for indications other than acute coronary syndrome

          -  Patient has platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3

          -  Patient has white blood cell (WBC) count &lt;3,000 cells/mm3

          -  Patient has documented or suspected liver disease, including laboratory evidence of
             hepatitis

          -  Patient is on dialysis or has known renal insufficiency (ie, estimated creatinine
             clearance &lt;50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight
             (in kg)]/[plasma creatinine (mg/dl)*72])

          -  Patient has history of bleeding diathesis or coagulopathy or will refuse blood
             transfusions

          -  Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)
             within past 6 months, or has any permanent neurologic defect that may cause
             non-compliance with the protocol

          -  Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon
             angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index
             procedure

          -  Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by
             visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting
             balloon, atherectomy) at any time prior to index procedure

          -  Non-target vessel or side branch has been treated with any type of PCI (eg, balloon
             angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to index
             procedure

          -  Planned or actual target vessel(s) treatment with an unapproved device, directional or
             rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction
             catheter immediately prior to stent placement

          -  Planned PCI or CABG after index procedure

          -  Patient previously treated at any time with coronary intravascular brachytherapy

          -  Patient has a known allergy to the study stent system or protocol-required concomitant
             medications (eg, stainless steel, platinum, cobalt, chromium, nickel, tungsten,
             acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot
             be adequately premedicated

          -  Patient has active peptic ulcer or active gastrointestinal (GI) bleeding

          -  Patient has one of the following.

               -  Other serious medical illness (eg, cancer, congestive heart failure) that may
                  reduce life expectancy to less than 24 months

               -  Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)

               -  Planned procedure that may cause non-compliance with protocol or confound data
                  interpretation

          -  Patient is participating in another investigational drug or device clinical trial that
             has not reached its primary endpoint

          -  Patient intends to participate in another investigational drug or device clinical
             trial within 12 months after index procedure

          -  Patient with known intention to procreate within 12 months after index procedure
             (Women of child-bearing potential who are sexually active must agree to use a reliable
             method of contraception from the time of screening through 12 months after the index
             procedure.)

          -  Patient is a woman who is pregnant or nursing (A pregnancy test must be performed
             within 7 days prior to the index procedure in women of child-bearing potential)

          -  Patient has more than 2 target lesions, or more than 1 target lesion and 1 non-target
             lesion, which will be treated during the index procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter M Maurer, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bakersfield Memorial Hospital</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediquest Research at Munroe Regional Medical Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital &amp; St. Mary's Healthcare</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Michigan Hospital</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses H. Cone Memorial Hospital/LeBauer Cardiovascular Research Foundation</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Medical Center</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research and Education at The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Health Research and Innovation Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Foundation for Cardiovascular Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Heart &amp; Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TexSAn Heart Hospital</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <zip>VIC 3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hôpital Universitaire Rangueil</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex 9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shonan Kamakura General Hospital</name>
      <address>
        <city>Kamakura-shi</city>
        <state>Kanagawa-ken</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurabashi Watanabe Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Hospital</name>
      <address>
        <city>Takapuna</city>
        <zip>0622</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Japan</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2011</study_first_submitted>
  <study_first_submitted_qc>December 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2011</study_first_posted>
  <results_first_submitted>January 10, 2012</results_first_submitted>
  <results_first_submitted_qc>January 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2012</results_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-eluting stents</keyword>
  <keyword>DES</keyword>
  <keyword>atherosclerotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Primary endpoints uploaded</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment of 94 patients was planned and 94 patients were enrolled at 23 sites in Australia, Belgium, France, Japan, New Zealand, and the United States from February 9, 2009 to December 10, 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PROMUS Element</title>
          <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed 12-month visit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PROMUS Element</title>
          <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.33" spread="11.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black of African heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>Participant</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Previous Percutaneous Coronary Intervention (PCI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous Coronary Artery Bypass Graft (CABG)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previous Myocardial Infarction (MI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Congestive Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unstable Angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Silent Ischemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac History: Ejection Fraction</title>
          <units>ejection fraction percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.07" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac Risk Factors</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Smoking, Ever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically Treated Diabetes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia Requiring Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension Requiring Medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family History of Coronary Artery Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of Peripheral Vascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Transient Ischemic Attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Cerebrovascular Accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Renal Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of Gastrointestinal Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic: Target Lesion Vessel</title>
          <units>lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Left Anterior Descending Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Circumflex Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Coronary Artery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic: Lesion Location</title>
          <units>Lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Ostial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mid</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics</title>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Reference Vessel Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.04" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum Lumen Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.51" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lesion Length</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.15" spread="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic: Percent Diameter Stenosis</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.10" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics</title>
          <description>The same participant may be included in more than one category therefore the number of participants for this baseline measure does not equal the total number of participants in the group.</description>
          <units>lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Eccentric Lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 45 Degree Bend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 90 Degree Bend</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tortuosity, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcification, any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bifurcation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristics: American College of Cardiology (ACC)/American Heart Association (AHA) Class</title>
          <description>Type A lesions: minimally complex, readily accessible, non-angulated, smooth contour, little to no calcification, less than totally occlusive, not ostial in location, no major side branch involvement, and an absence of thrombus.
Type B lesions: moderately complex, eccentric, moderate tortuosity and angulation, moderate or heavy calcification, total occlusion &lt; 3 months old, ostial in location, with presence of thrombus.
Type C lesions: severely complex, diffuse, excessive tortuosity and angulation, total occlusions &gt; 3 months old, degenerated vein grafts and friable lesions.</description>
          <units>lesions</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Type A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type B2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lesion Characteristic - Pre-Procedure Thrombolysis In Myocardial Infarction (TIMI) Flow</title>
          <description>TIMI 0 - No perfusion; TIMI 1 - Penetration with minimal perfusion; TIMI 2 - Partial perfusion; TIMI 3 - Complete perfusion</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>TIMI 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TIMI 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel. The primary analysis set for the non-inferiority testing of the primary endpoint is the per-protocol analysis set. All randomized participants who received their assigned treatment are included in the per-protocol analysis set.</description>
        <time_frame>12 Months</time_frame>
        <population>The primary analysis set for comparison of the primary endpoint, 12-month TLF, to the predefined performance goal of 21.1% (based on historical TAXUS Express results) is the per-protocol analysis set. All enrolled participants who received a PROMUS Element stent are included in the per-protocol analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel. The primary analysis set for the non-inferiority testing of the primary endpoint is the per-protocol analysis set. All randomized participants who received their assigned treatment are included in the per-protocol analysis set.</description>
          <population>The primary analysis set for comparison of the primary endpoint, 12-month TLF, to the predefined performance goal of 21.1% (based on historical TAXUS Express results) is the per-protocol analysis set. All enrolled participants who received a PROMUS Element stent are included in the per-protocol analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>A one-group exact binomial test was used to test the hypothesis that the primary endpoint rate in the PROMUS Element cohort is less than the predefined performance goal of 21.1%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>One-group exact binomial test</method>
            <param_type>Percent Target Lesion Failure</param_type>
            <param_value>2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Failure (TLF)</title>
        <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
        <time_frame>30 Days</time_frame>
        <population>Analysis was intention to treat; all participants underwent clinical follow-up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Failure (TLF)</title>
          <description>Defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel.</description>
          <population>Analysis was intention to treat; all participants underwent clinical follow-up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
        <time_frame>12 Months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
        <time_frame>6 Months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Failure (TVF)</title>
        <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
        <time_frame>30 Days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Failure (TVF)</title>
          <description>Target vessel failure (TVF) is defined as any ischemia-driven revascularization of the target vessel, myocardial infarction (MI;Q-wave and non–Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
        <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
        <time_frame>12 Months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
          <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with MI</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
        <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
          <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with MI</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
        <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI) Related to the Target Vessel</title>
          <description>New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase myoglobin band(CK-MB) or troponin &gt;upper limit of normal(ULN); if no new Q-waves total CK levels &gt;3×ULN (peri-percutaneous coronary intervention [PCI]) or &gt;2×ULN (spontaneous) with elevated CK-MB or troponin &gt;3×ULN (peri-PCI) or &gt;2×ULN (spontaneous) plus ≥one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin &gt;5×ULN</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with MI</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death Related to the Target Vessel</title>
        <description>Defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death Related to the Target Vessel</title>
          <description>Defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death Related to the Target Vessel</title>
        <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death Related to the Target Vessel</title>
          <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiac Death Related to the Target Vessel</title>
        <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Death Related to the Target Vessel</title>
          <description>Cardiac death is defined as death due to any of the following: acute myocardial infarction (MI); cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded; see definition of MI above</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR)</title>
          <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with TLR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR)</title>
          <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with TLR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization TLR)</title>
        <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization TLR)</title>
          <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with TLR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
        <time_frame>12 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR)</title>
          <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with TVR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
        <time_frame>6 months</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR)</title>
          <description>Defined as any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with TVR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TVR)</title>
        <description>Any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
        <time_frame>30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TVR)</title>
          <description>Any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with TVR</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC)Definition</title>
        <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
        <time_frame>24 hours</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC)Definition</title>
          <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with ST</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
        <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
        <time_frame>&gt;24 hr-30 days</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
          <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with ST</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
        <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
        <time_frame>&gt;30 days-1 year</time_frame>
        <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition</title>
          <description>DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: &gt;24 hours to 30 days post; late ST: &gt;30 days to 1 year post; Very late ST: &gt;1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days)</description>
          <population>Analysis was intention to treat; all patients in the study underwent clinical follow up to provide the information needed for this endpoint.</population>
          <units>percentage of participants with ST</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Technical Success</title>
        <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
        <time_frame>During the index procedure (minutes)</time_frame>
        <population>Analysis was intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Technical Success</title>
          <description>Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent</description>
          <population>Analysis was intention to treat</population>
          <units>percentage of stents</units>
          <param>Number</param>
          <units_analyzed>stents</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>stents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Procedural Success</title>
        <description>Defined as mean lesion diameter stenosis &lt;30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital MI, TVR, or cardiac death.</description>
        <time_frame>Duration of Hospital Stay (average 1-2 days)</time_frame>
        <population>Analysis was intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PROMUS Element</title>
            <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Procedural Success</title>
          <description>Defined as mean lesion diameter stenosis &lt;30% with visually assessed TIMI 3 flow and without the occurrence of in-hospital MI, TVR, or cardiac death.</description>
          <population>Analysis was intention to treat</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PROMUS Element</title>
          <description>Patients enrolled in the study to receive treatment with the PROMUS Element everolimus-eluting stent</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Coronary artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Gunshot wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Catheter site haematoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Principal Investigator (PI) shall have the right to publish the results, provided that before publishing, the PI shall submit copies of any proposed publication or presentation to the Sponsor for review at least 45 days in advance of submission for publication or presentation to a publisher or other third party. Sponsor reserves the right to delete any confidential information or other proprietary information of Sponsor from the proposed publication or presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ruth M. Starzyk, PhD</name_or_title>
      <organization>Boston Scientific</organization>
      <phone>508-683-6577</phone>
      <email>ruth.starzyk@bsci.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

